| 4.51 0.06 (1.35%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.37 |
1-year : | 5.65 |
| Resists | First : | 4.59 |
Second : | 4.84 |
| Pivot price | 4.46 |
|||
| Supports | First : | 4.21 |
Second : | 3.5 |
| MAs | MA(5) : | 4.42 |
MA(20) : | 4.47 |
| MA(100) : | 4.31 |
MA(250) : | 3.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 34 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 5.34 | Low : | 1.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed below upper band by 41.0%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.71 - 4.73 | 4.73 - 4.75 |
| Low: | 4.43 - 4.45 | 4.45 - 4.48 |
| Close: | 4.48 - 4.51 | 4.51 - 4.54 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sat, 14 Sep 2024
Geron Corp. (GERN): Short Seller Sentiment is Bearish on This Cancer Stock - Insider Monkey
Thu, 12 Sep 2024
Geron Corp. (GERN): Fast-Growing Penny Stock To Consider - Yahoo Finance
Thu, 12 Sep 2024
Geron Corporation (NASDAQ:GERN): Hedge Funds Are Bullish On This US Stock to Buy Under $5 Now - Yahoo Finance
Thu, 12 Sep 2024
Best Penny Stocks of September 2024 - USA TODAY
Mon, 09 Sep 2024
Geron Corporation appoints new Chief Commercial Officer - Investing.com
Mon, 09 Sep 2024
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -127 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.028e+008 (%) |
| Held by Institutions | 5.5588e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 860.8 % |
| Return on Equity (ttm) | -32.9 % |
| Qtrly Rev. Growth | 1.37e+006 % |
| Gross Profit (p.s.) | -127.38 |
| Sales Per Share | -184.09 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2677e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | -2.6 |
| Price to Book value | -12.89 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0 |
| Dividend | 6.714e+007 |
| Forward Dividend | 5.786e+007 |
| Dividend Yield | 1488690000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|